Categories
- Aesthetic Medicine
- Aesthetic Surgery
- Ai
- ALS Treatment
- Anatomy
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Batten Disease Treatment
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Bitcoin
- Brain Injury Treatment
- Cardiac Nursing
- Cardiac Regeneration
- Cardiac Remodeling
- Cardiac Rhythm Abnormalities
- Cardiac Surgery
- Cardiology
- Cardiomyopathies
- Cardiovascular Pharmacology
- Cell Medicine
- Cell Therapy
- Cerebral Palsy
- Cerebral Palsy Treatment
- Cheap Pharmacy
- Chemistry
- Clinical Cardiology
- Coronary Heart Diseases
- Cryptocurrency
- DNA
- Drug Dependency
- Drug Side Effects
- Drugs
- Eczema
- Elon Musk
- Embryology
- Erectile Dysfunction
- FDA Stem Cell Trials
- Femtomedicine
- Future Medicine
- Gene Medicine
- Gene Therapy
- Gene Therapy Trials
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Heart Diseases
- HGH
- Hgh Injections
- Hormone Replacement Therapy
- Human Genetics
- Human Growth Hormone
- Human Immortality
- Hyperbaric Medicine
- Hypertension
- Hypothalamus
- Impotency
- Internet Pharmacy
- Interventional Cardiology
- IVF Treatment
- Lyme Disease
- Male Sexual Dysfunction
- Mars Colony
- Medical Business
- Medical School
- Medical Technology
- Medicine
- Mental Health
- Mesenchymal Stem Cells
- Micropenia
- Molecular Cardiology
- MS Treatment
- Muscular Dystrophy Treatment
- Myocardial Infarction
- Nanotechnology
- Online Pharmacy
- Oral Health
- Parkinson's Treatment
- Pediatric Cardiology
- Penis Enlargement
- Pet Stem Cell Therapy
- Pharmacy
- Picomedicine
- Premature Ejaculation
- Prescriptions
- Retinitis Pigmentosa
- Sermorelin
- Singularity
- Sleep
- Spacex
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Testosterone
- Ulcerative Colitis
- Uncategorized
- Vascular Biology
- Ventricular Remodeling
- Wholesale Pharmacy
Archives
Monthly Archives: July 2012
SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video
Posted: Published on July 2nd, 2012
02-07-2012 09:43 State of the Nation is a nightly newscast anchored by award-winning broadcast journalist, Jessica Soho. It airs Mondays to Fridays at 9:00 PM (PHL Time) on GMA News TV Channel 11. For more videos from State of the Nation, visit fthenation. View post: SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan - Video … Continue reading
Posted in Cell Therapy
Comments Off on SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video
Generating dopamine via cell therapy for Parkinson’s disease
Posted: Published on July 2nd, 2012
Public release date: 2-Jul-2012 [ | E-mail | Share ] Contact: Sarah Jackson press_releases@the-jci.org Journal of Clinical Investigation In Parkinson's disease, the loss of dopamine-producing cells in the midbrain causes well-characterized motor symptoms. Though embryonic stem cells could potentially be used to replace dopaminergic (DA) neurons in Parkinson's disease patients, such cell therapy options must still overcome technical obstacles before the approach is ready for the clinic. Embryonic stem cell-based transplantation regimens carry a risk of introducing inappropriate cells or even cancer-prone cells. To develop cell purification strategies to minimize these risks, Dr. Lorenza Studer and colleagues at Memorial Sloan Kettering Cancer Center in New York developed three different mouse lines to fluorescently label dopaminergic neurons at early, mid, and late stages of differentiation. Their data suggest that mouse embryonic stem cells induced to the mid stage of neuronal differentiation are best suited for transplantation to replace dopaminergic neurons. Further, their work identified new genes associated with each stage of neuronal differentiation. Their results in the mouse model system help define the differentiation stage and specific attributes of embryonic stem cell-derived, dopamine-generating cells that hold promise for cell therapy applications. ### TITLE: Identification of embryonic stem cellderived midbrain dopaminergic neurons … Continue reading
Posted in Cell Therapy
Comments Off on Generating dopamine via cell therapy for Parkinson’s disease
Generating dopamine via cell therapy for Parkinson's disease
Posted: Published on July 2nd, 2012
Public release date: 2-Jul-2012 [ | E-mail | Share ] Contact: Sarah Jackson press_releases@the-jci.org Journal of Clinical Investigation In Parkinson's disease, the loss of dopamine-producing cells in the midbrain causes well-characterized motor symptoms. Though embryonic stem cells could potentially be used to replace dopaminergic (DA) neurons in Parkinson's disease patients, such cell therapy options must still overcome technical obstacles before the approach is ready for the clinic. Embryonic stem cell-based transplantation regimens carry a risk of introducing inappropriate cells or even cancer-prone cells. To develop cell purification strategies to minimize these risks, Dr. Lorenza Studer and colleagues at Memorial Sloan Kettering Cancer Center in New York developed three different mouse lines to fluorescently label dopaminergic neurons at early, mid, and late stages of differentiation. Their data suggest that mouse embryonic stem cells induced to the mid stage of neuronal differentiation are best suited for transplantation to replace dopaminergic neurons. Further, their work identified new genes associated with each stage of neuronal differentiation. Their results in the mouse model system help define the differentiation stage and specific attributes of embryonic stem cell-derived, dopamine-generating cells that hold promise for cell therapy applications. ### TITLE: Identification of embryonic stem cellderived midbrain dopaminergic neurons … Continue reading
Posted in Cell Therapy
Comments Off on Generating dopamine via cell therapy for Parkinson's disease
China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2012 Earnings Results and Schedules Conference Call for July 3, 2012
Posted: Published on July 2nd, 2012
HANGZHOU, China--(BUSINESS WIRE)-- China Jo-Jo Drugstores, Inc. (CJJD) (the Company), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today reported earnings results for the fiscal year ended March 31, 2012. The Company will hold a conference on Tuesday, July 3, 2012, at 8:00 a.m. Eastern Time. Please see below for dial-in information. Mr. Lei Liu, the Companys Chairman and CEO, stated, During fiscal year 2012, we faced a continually challenging regulatory environment as more over-the-counter and prescription drugs were subject to price controls and new restrictions were enacted which curtailed our ability to promote in Hangzhou where most of our pharmacies are located. Nevertheless, we plan to continue opening new stores in the coming fiscal year. During the three months ended March 31, 2012, the Company opened two pharmacies, including at premium locations designed to meet the needs of more affluent customers. As of June 26, 2012, the Company operated 64 retail pharmacy locations. In light of the challenges we are facing, however, we have pushed forward on our vertical integration strategy in order to reduce our reliance on retail pharmacy sales, starting with our acquisition of Zhejiang Jiuxin Medicine Co., Ltd., a wholesale distributor, … Continue reading
Posted in Wholesale Pharmacy
Comments Off on China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2012 Earnings Results and Schedules Conference Call for July 3, 2012
Murder trial told of drugs binge
Posted: Published on July 2nd, 2012
2 July 2012 Last updated at 11:17 ET A murder accused has told a jury he remembered little of the night he was alleged to have killed his best friend after an all-day drink and drug binge. Derek Kinghorn, 44, said he only became aware of anything untoward when he felt blood on his face from a head wound. He remembered drinking 10 cans of beer and smoking several cannabis joints earlier in the day. Mr Kinghorn denies murdering Brian Mair and assaulting Amy Michaels in his Hawick home in November last year. He told the High Court in Livingston that he and Mr Mair had been playing Playstation games and drinking and taking drugs since 10:00 on the day in question. Just before 19:00 Mr Kinghorn phoned a dealer to have more drugs delivered. He claimed the large kitchen knife, identified as the murder weapon, would have been brought into the room to divide up a lump of cannabis resin although he could not remember this happening. Mr Kinghorn said he had no memory of going out drinking at The Imperial Bar in Hawick with Mr Mair after the drugs had been delivered to his house. He said he … Continue reading
Posted in Drugs
Comments Off on Murder trial told of drugs binge
A Glut of Obesity Drugs?
Posted: Published on July 2nd, 2012
On June 27, the FDA approved the first new weight-loss drug in 13 years, Arenas lorcaserin (Belviq). The track record for anti-obesity drugs has not been very goodeach has been withdrawn from the market, after approval, due to safety concerns. Why was this drug approved? How long will this one last before being yanked for adverse events? Lets look at the background and track record of lorcaserins predecessors. Perspective on the need for weight loss drugs Why the brouhaha over Arenas new drug? According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese, defined as having a Body-Mass Index (BMI) of > 35. In the U.S. alone, 78 million U.S. adults are obese; another 34% of adults are overweight > 30. So 70% of U.S. adults have a problem with weight. Worldwide, CDC estimates 500 million are currently affected. Overweight and obesity constitute the second leading cause of preventable death, after smoking, resulting in an estimated 300,000 deaths per year. The number of obese is expected to rise to 42% by 2030, with an additional 11% prevalence of severe obesity (BMI >40, or ~80+ lbs overweight). In 2000, consumers spent … Continue reading
Posted in Drugs
Comments Off on A Glut of Obesity Drugs?
2000-plus schoolkids caught with drugs
Posted: Published on July 2nd, 2012
Students were caught with drugs in 2173 incidents at school last year and the youngest child to be stood down was in year 3. But the figure is the lowest in three years, according to preliminary data. Last year, there were 1324 stand-downs and 849 suspensions in New Zealand schools for drug-related behaviour (including substance abuse), according to figures released to the Herald. The Ministry of Education said the data was still being updated by schools and so could not be compared with other years, but previous figures have quoted there being 2441 drug incidents in 2009 and 2690 in 2010. A year 3 student - aged between 7 and 8 - was stood down in the Manawatu-Wanganui region. The youngest to be suspended were two year 5 students - aged between 9 and 10 - in Gisborne and Wellington. Gisborne had the highest number of incidents per capita where students were caught with drugs, with a total of 77 suspensions and stand-downs from a roll of 9353. A stand-down is the removal of a learner for a period of up to five days, with the decision made by the principal. A suspension is the formal removal of a student … Continue reading
Posted in Drugs
Comments Off on 2000-plus schoolkids caught with drugs
SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video
Posted: Published on July 2nd, 2012
02-07-2012 09:43 State of the Nation is a nightly newscast anchored by award-winning broadcast journalist, Jessica Soho. It airs Mondays to Fridays at 9:00 PM (PHL Time) on GMA News TV Channel 11. For more videos from State of the Nation, visit fthenation. See the rest here: SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan - Video … Continue reading
Comments Off on SONA: Stem cell therapy, kaya raw makapagpabata ng pangangatawan – Video
Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European …
Posted: Published on July 2nd, 2012
CARMIEL, Israel, July 2, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (PLX) (PLX) announced today that new clinical data on taliglucerase alfa was presented at the 10th Annual European Working Group on Gaucher Disease Meeting that took place June 28-30 in Paris, France. Taliglucerase alfa is approved in the United States as an enzyme replacement therapy for the treatment of adults with type 1 Gaucher disease. Laura van Dussen, M.D., of the Academic Medical Center, University of Amsterdam, presented long-term bone marrow responses in Gaucher patients from the Company's pivotal and extension trials. Bone marrow imaging can be used as an important indicator for determining bone risk potential for Gaucher patients. Bone marrow fat fractions of eight naive patients from the pivotal and extension trials who were treated with taliglucerase alfa for at least 36 months, and 15 untreated Gaucher patients, were evaluated using Quantitative Chemical Shift Imaging (QCSI) MRI. At 36 months, the patients treated with taliglucerase alfa demonstrated a significant improvement in fat fraction from baseline (p-value = 0.012 after 36 months of follow-up). The range of absolute fat fraction values was between 0.19% and 0.42%, which corresponds to a mean change of 92% from baseline of fat … Continue reading
Posted in FDA Stem Cell Trials
Comments Off on Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European …
Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart …
Posted: Published on July 2nd, 2012
COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), announced today interim one-year results from its groundbreaking clinical trial evaluating Prochymal (remestemcel-L) for the treatment of patients experiencing first-time acute myocardial infarction. The trial is the largest study of allogeneic or "off-the-shelf" stem cells ever conducted in heart attack patients. A total of 220 patients were given a single infusion of either Prochymal or placebo through a standard intravenous line within seven days of an acute heart attack. Cardiac MRI assessments were conducted for six months following infarct to evaluate cardiac remodeling. Patients receiving Prochymal had significantly less cardiac hypertrophy, as measured by cardiac MRI, compared to patients receiving placebo (p … Continue reading
Posted in Stem Cell Human Trials
Comments Off on Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart …